Prescient Therapeutics Ltd
PTX
Company Profile
Business description
Prescient Therapeutics Ltd is a clinical-stage oncology company. The company develops novel compounds for the treatment of a range of cancers in Australia. Its product in the pipeline includes OmniCAR; PTX-100 and PTX-200. OmniCAR is a universal immune receptor platform enabling controllable T-cell activity and multi-antigen targeting with a single cell product.
Contact
385 Bourke Street
Suite 2, Level 11
MelbourneVIC3200
AUST: +61 396927222
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2026
Employees
1
Stocks News & Analysis
stocks
Fair value lifts for toll road operator as Aussie fuel supply steadies
An Australian fuel shortage is becoming increasingly unlikely, a relief for ASX toll road operator.
stocks
Wide moat stock exchange remains cheap
Aussie stock exchange remains materially undervalued despite growing cost concerns.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,945.40 | 1.20 | -0.01% |
| CAC 40 | 8,183.34 | 5.53 | -0.07% |
| DAX 40 | 25,104.70 | 12.45 | 0.05% |
| Dow JONES (US) | 51,032.46 | 363.49 | 0.72% |
| FTSE 100 | 10,409.28 | 16.68 | -0.16% |
| HKSE | 25,182.39 | 176.23 | 0.70% |
| NASDAQ | 26,972.62 | 55.15 | 0.20% |
| Nikkei 225 | 67,044.70 | 715.20 | 1.08% |
| NZX 50 Index | 13,244.55 | 38.44 | 0.29% |
| S&P 500 | 7,580.06 | 16.43 | 0.22% |
| S&P/ASX 200 | 8,706.70 | 3.30 | -0.04% |
| SSE Composite Index | 4,068.34 | 0.23 | -0.01% |